Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Markers Found for Early Detection of Type 1 Diabetes

By LabMedica International staff writers
Posted on 20 Oct 2009
German researchers have identified new markers that enable an early diagnosis and prognosis of type 1 diabetes.

German scientist investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. More...
The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome. These high-risk individuals require especially careful monitoring.

The research was performed under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München (Germany) and Technische Universität München (Germany).

Worldwide, the number of children who develop type 1 diabetes is increasing. In Germany, approximately 11,000 children are affected. On average, they are eight and a half years old when they are diagnosed with the disease. However, already at this age many children show severe metabolic decompensation. Successful prevention strategies and detailed screening can prevent this.

Prof. Dr. Anette Ziegler and Dr. Peter Achenbach, from Helmholtz Zentrum München and Technische Universität München in cooperation with Prof. Dr. Ezio Bonifacio of Technische Universität Dresden, have developed a new approach to improve and extend risk screening. "Acute severe complications such as diabetic coma at disease onset can thus be avoided in the majority of the children,” Dr. Peter Achenbach explained. The scientists evaluated the data of 1,633 children who had at least one type 1 diabetic parent. These children's risk for diabetes was elevated in comparison with children who had no family history of diabetes.

Genetic factors play a considerable role in the development of type 1 diabetes. The scientists were able to show that specific variants of the zinc transporter gene SLC30A8 influence the risk for diabetes. The body needs this gene in order to produce ZnT8. This protein influences the zinc transport into the beta cells and plays a crucial role in their maturation and thus also in insulin secretion.

Beta cells of the islets of Langerhans in the pancreas secrete the critically important insulin. Already before the onset of type 1 diabetes the body's own immune system destroys the beta cells. If this destruction exceeds a certain threshold, the disease becomes evident: The insulin deficiency leads to various metabolic disturbances, including elevated blood glucose levels.

"Autoantibodies to ZnT8 in combination with a specific variant of the zinc transporter gene were associated with an elevated diabetes risk,” said Dr. Peter Achenbach, from the Institute for Diabetes Research at Helmholtz Zentrum München. "Eighty-one percent of these children with ZnT8 antibodies developed diabetes mellitus.” An increased diabetes risk has long been associated with the islet autoantibodies. These include the autoantibodies to insulin (IAA), islet cell antibodies to the enzyme glutamate decarboxylase (GADA) and to tyrosine phosphatases (IA-2A and IA-2ß).

"Autoantibodies to ZnT8 are an additional important marker for the progression of diabetes--especially in children who are already developing islet autoantibodies,” said Dr. Thomas Illig, from the Institute of Epidemiology at Helmholtz Zentrum München. A differentiated analysis of all autoantibodies allows the prognosis of how fast the disease will become manifest. According to Dr. Illig, the rule of thumb is: The larger the number of different kinds of autoantibodies, the higher the risk for diabetes, and the younger the child with autoantibodies, the earlier disease onset will be.

The study was published in the September 2009 issue of the journal Diabetolgia
Related Links:
Helmholtz Zentrum München
Technische Universität München





Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.